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to HD. Interestingly, clinical responders to ipilimumab 
therapy showed significantly less lin− CD14+ HLA-DR− 
cells as compared to non-responders. The data suggest that 
the frequency of monocytic MDSC may be used as pre-
dictive marker of response, as low frequencies identify 
patients more likely benefitting from ipilimumab treat-
ment. Prospective clinical trials assessing MDSC frequen-
cies as potential biomarkers are warranted to validate these 
observations.
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Introduction
Primary melanomas in early stages are curable by sur-
gery. After metastasis formation, however, patients have 
a median survival of <1 year. Chemotherapy may induce 
occasional tumor responses [1] but does not improve over-
all survival. Until 2010, long-term responses in metastatic 
melanoma were achieved only after adoptive transfer of 
autologous T cells [2], a therapy applicable to a selected 
minority of patients with good performance status, or after 
high dose IL-2 treatment [3].
About 50 % of melanomas express BRAF-activating 
mutations [4], which are V600E and V600K substitutions 
in 95 % of cases [5]. Treatment with BRAF inhibitors, 
MEK inhibitor, or a combination of both prolonged pro-
gression-free survival [5–7]. Despite these great advances, 
patients treated with BRAF or MEK inhibitors experience 
disease progression after a mean of about 6 months [7]. 
Recently, the fully humanized anti-CTLA-4 antibody ipili-
mumab was reported to increase overall survival of stage 
III/IV metastatic melanoma patients [8, 9]. The treatment 
received FDA approval for non-resectable and metastatic 
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monitoring is the identification of biomarkers that predict 
clinical outcome. We studied circulating myeloid-derived 
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tended to increase in patients with severe metastatic dis-
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lymph nodes only (M1a), who had frequencies comparable 
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melanoma in March 2011 [10]. CTLA-4 is expressed on 
activated T cells, serving as “immune checkpoint” mole-
cule which prevents overwhelming cytotoxicity and conse-
quent autoimmunity and tissue damage. Upon activation, T 
cells express CTLA-4 which binds to its ligands CD80 and 
CD86 with higher affinity than CD28. Several mechanisms 
of action have been proposed explaining the strong effect 
of CTLA-4 blockade [11].
It is well accepted that tumor-reactive T cells in vivo 
upregulate CTLA-4. In situ, they show an exhausted, less 
functional phenotype [12]. Treatment with the CTLA-
4-blocking antibody ipilimumab increased T cell activation 
[13] and their proliferation [14] in stage III/IV melanoma 
patients. Higher T cell activation correlates with tumor 
regression or disease stabilization in about 11–13 % of 
patients [8, 15]. However, autoimmune responses are also 
promoted, as 10–15 % of patients develop severe grade 
3–4 immune-related adverse events [8]. Interestingly, 
these autoimmune manifestations correlate with clinical 
responses [15].
Tumor lesions may increase in size with the onset of 
inflammation during ipilimumab treatment, followed by 
size reductions frequently several months after the com-
pletion of ipilimumab dosing [16]. Traditional tumor 
response criteria are therefore not fully appreciating the 
clinically relevant effects of anti-CTLA-4 treatment. The 
new immune-related response criteria take into account that 
clinical responses can develop late, possibly only after ini-
tial tumor mass increase due to inflammation [17]. These 
criteria have already proven to be highly relevant for onco-
immunological-patient assessments [18], despite that they 
are not yet fully established for phase III studies. Accord-
ing to these criteria, the first tumor assessment is performed 
12 weeks after therapy start.
Identification of biomarkers that are associated with 
clinical responses to ipilimumab may help to identify 
patients likely to benefit from the treatment. In bladder can-
cer, increased frequencies of CD4+ ICOShigh T cells cor-
related with a better clinical outcome [19]. For melanoma, 
this correlation remains to be confirmed as results are con-
troversial [14, 20]. Absolute lymphocyte counts after 2 
infusions of ipilimumab [18] and the presence of NY-ESO-
1-specific antibodies and of specific CD8+ T cells [21] 
correlated positively with clinical outcome in melanoma. 
Furthermore, high levels of Ki67+ EOMES+ CD8+ T cells 
were associated with improved relapse-free survival in mel-
anoma patients [14].
While most studies focused on T cell and antibody 
responses in patients treated with ipilimumab [13, 14, 
20–24], we were particularly interested in studying mye-
loid cells. In humans, several myeloid-derived suppressor 
cells (MDSC) subpopulations have been described termed 
monocytic and granulocytic MDSC, respectively [25–28]. 
Different malignancies favor the accumulation of different 
MDSC phenotypes in patients [29]. In melanoma patients, 
circulating CD14+ HLA-DR− MDSC were described to 
be enriched as compared to healthy donors (HD) [30–32]. 
However, MDSC also vary between different studies of the 
same cancer type, e.g., human renal cell carcinoma [33–
35]. MDSC in humans are widely accepted to have low or 
absent HLA-DR expression [25–28], whereas some experi-
mental mouse models showed that MHC-II expression on 
MDSC may be important for suppression of CD4+ T cells 
[36].
In our study of patients treated with CTLA-4-blocking 
antibody, we hypothesized that improved T cell activity 
with stronger proliferation [14] and enhanced cytokine 
secretion [23] might be paralleled with alterations in the 
myeloid cell compartment. For example, IFN-γ produc-
tion may play a role because it contributes to MDSC 
recruitment [37]. Besides the known T cell intrinsic 
mechanisms of CTLA-4, several T cell extrinsic path-
ways have been described, for instance by competition 
for co-stimulation via CD80/CD86 (B7), or B7-mediated 
outside-in-signaling altering myeloid cells, particularly 
antigen-presenting cells, in their capacity to activate or 
tolerize immune responses [38]. To obtain more informa-
tion about mechanisms regulating immune responses in 
cancer patients, we analyzed MDSC in peripheral blood 
of advanced melanoma patients receiving the standard 
regimen of 4 3-weekly infusions of ipilimumab (3 mg/kg). 
Our results show significant correlations between frequen-
cies of monocytic MDSC and clinical responses in patients 
treated with ipilimumab.
Materials and methods
Patient population and study design
Human sample collection and use adhered to protocols 
approved by the Institutional Review and Privacy Board 
of the University Hospital of Lausanne (CHUV, Lausanne, 
Switzerland). All patients gave informed consent prior to 
study inclusion. We analyzed peripheral blood samples 
from 49 patients (23 females, 26 males), ≥18 years of age 
and with AJCC stage IV or unresectable stage III malignant 
melanoma, histologically confirmed (Tables 1, 2). Fifteen 
healthy blood donors (9 females, 6 males) served as con-
trols (Table 1). Patients treated with ipilimumab (Table 2) 
had to undergo at least one first-line chemotherapeutic 
treatment without clinical response before receiving ipili-
mumab second-line. Patients were treated intravenously 
with 4 cycles of 3 mg/kg ipilimumab every 3 weeks. Blood 
samples were withdrawn at baseline and at 5-time points 
during the treatment: day 3 after treatment 1 (t1d3), t1d7, 
249Cancer Immunol Immunother (2014) 63:247–257 
1 3
before t3, t3d7 and t4d20. Follow-up blood samples were 
obtained after 3–30 months post-treatment.
Calculation of MDSC frequencies
Whenever multiple blood samples were withdrawn from a 
patient during the course of treatment and follow-up, the 
average frequency per patient is given and indicated as such 
in the figure legends. The finding that MDSC values per 
patient do not change significantly over time makes aver-
age values meaningful. Otherwise, the indicated MDSC 
frequency corresponds to one blood sample per patient.
Assessment of clinical responses
Tumor response was assessed at week 12, 16 and/or 24 
following treatment with ipilimumab using the immune-
related response criteria [17]. Patients achieving complete 
responses (CR), partial responses (PR) or stable disease 
(SD) at week 12 or 16/24 post-ipilimumab were considered 
Table 1  Characteristics of healthy donors and melanoma patients 
and their treatment
The “All patients cohort” (N = 49) consist of stage III/IV melanoma 
patients with different melanoma treatment status. Twenty-three of 
them did not have had treatment for melanoma except tumor surgery 
at the time of blood sample and were included into the subgroup anal-
ysis for “untreated patients”
Fifteen patients received anti-CTLA-4 treatment and belong to the 
“study population treated with ipilimumab monotherapy.” Remaining 
patients (N = 11) received vemurafenib (N = 10) or ipilimumab with 
subsequent vemurafenib (N = 1) and were not analyzed separately. 
Fifteen HD served as controls
Characteristics of patients and healthy donors Number (range or %)
All patients (N = 49)
Median age at blood sample 63 (22–86)
Gender
 Female 23 (47 %)
 Male 26 (53 %)
Patients treated with
 No treatment 23 (47 %)
 Ipilimumab 15 (31 %)
 Ipilimumab followed by vemurafenib 1 (2 %)
 Vemurafenib 10 (20 %)
Untreated patients (N = 23)
Median age at blood sample 60 (22–79)
Gender
 Female 12
 Male 11
Tumor-bearing patients 17
Tumor-free patients 6
Median days after tumor surgery 30 (13–84)
Study population, i.e., patients treated with ipilimumab  
monotherapy (N = 15)
Median age at blood sample 65 (37–86)
Gender
 Female 5 (33.3 %)
 Male 10 (66.6 %)
Median month from study entry: (for more 
clinical details, see Table 2)
9 (1–23)
Healthy donors (N = 15)
Median age at blood sample 34 (22–71)
Gender
 Female 9 (60 %)
 Male 6 (40 %)
Table 2  Clinical details of melanoma patients treated with ipili-
mumab
PR partial response, CR complete response, SD stable disease, PD 
progressive disease, LDH serum lactate dehydrogenase
Characteristics of patients treated with  
ipilimumab monotherapy (N = 15)
Number of patients
Number of ipilimumab infusions
 2 1 (7 %)
 3 2 (13 %)
 4 12 (80 %)
Number of blood samples per patient during treatment and  
follow-up
 1 2 (13,33 %)
 2 1 (6,66 %)
 3 3 (20 %)
 4 1 (6,66 %)
 5 4 (26,66 %)
 6 4 (26,66 %)
Patients with baseline blood samples 8 (53 %)
Response to ipilimumab
 PR, CR 5 (33 %)
 SD 3 (20 %)
 PD 6 (40 %)
 Not evaluable 1 (7 %)
Previous treatments
 Radiotherapy 5 (33 %)
 Immunotherapy 6 (40 %)
AJCC stage at study entry
 III c 1 (7 %)
 IV M1a 4 (27 %)
 IV M1b 2 (13 %)
 IV M1c 8 (53 %)
ECOG performance status at study entry
 0–1 15 (100 %)
LDH at study entry (U/l)
 <225U/l 5 (33 %)
 >225U/l 9 (60 %)
 n.d. 1 (7 %)
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responders (R). Patients with progressive disease until 
week 16/24 post-ipilimumab were considered non-respond-
ers (NR).
LDH measurement
Serum lactate dehydrogenase (LDH) enzyme levels were 
judged increased if above 225 U/l, i.e., the institutional 
upper limit.
PBMC purification
Blood samples were withdrawn using tubes contain-
ing Li-heparin-coated beads (Sarstedt cat. no. 02.1065). 
Blood was centrifuged for 10 min at 1,500 rpm for 
plasma preservation and afterward PBMC were purified 
by density gradient centrifugation using Lymphoprep 
(Axis-Shield cat no. 1114547). Monocytic MDSC are 
enriched in the mononuclear cell layer; therefore, we did 
not perform whole blood stainings. All blood processing 
was performed within 3 h after blood withdrawal, and 
PBMC were used for flow cytometric analysis without 
cryopreservation.
Flow cytometry and antibodies
Freshly purified PBMC were incubated with human Fc 
receptor-blocking reagent (Miltenyi cat. no. 130-059-901) 
before staining with monoclonal antibodies against human 
CD3 (PE-labeled, BD cat. no. 345765), CD14 (Pacific 
blue-labeled, BD cat. no. 558121), CD19 (PE-labeled, 
Beckman Coulter cat. no. 6603024), CD56 (PE-labeled, 
BD cat. no. 345810), CTLA-4 (APC-labeled, BD cat no. 
555855), HLA-DR (ECD labeled, Beckman Coulter cat. 
no. IM3636), HLA-DR (PerCP-Cy5.5-labeled, Biolegend 
cat. no. 307630) and IL-4R-alpha (APC-labeled, R&D 
cat no. FAB230A) or IgG2-alpha isotype control (APC-
labeled, R&D cat no. IC003A). Dead cells were detected 
with vivid fixable live dead marker (near IR) (Invitrogen 
cat. no. L10119). Data were acquired on a Gallios flow 
cytometer (Beckman Coulter) and analyzed using FlowJo 
9.1 (TreeStar).
Statistical analysis
Statistical analyses were performed by GraphPad Prism 5 
software using parametric t test. When comparing samples 
of the same patient before and after treatment initiation, a 
paired-t test was used (Fig. 3b). A value of p < 0.05 was 
considered statistically significant. Results from multi-
ple samples per patient (dependent values) were analyzed 
using Bonferroni correction (Fig. 3a). A value of p < 0.01 
was considered statistically significant.
Results
Patients
The present study analyzed 49 malignant melanoma 
patients between September 2010 and October 2012. Fif-
teen healthy blood donors served as controls. The charac-
teristics of the HD and patients as well as their treatment 
are provided in Table 1. Fifteen of the patients received ipil-
imumab treatment with 4 cycles of 3 mg/kg every 3 weeks. 
Details of ipilimumab-treated patients, their treatments and 
the blood samples obtained are summarized in Table 2.
MDSC are significantly enriched in melanoma patients
In order to study whether anti-CTLA-4 therapy has any 
effects on monocytic MDSC recruitment and whether 
MDSC are associated with therapeutic outcome, we char-
acterized monocytic MDSC in stage III and IV melanoma 
patients.
First, we asked the question whether MDSC are 
enriched in melanoma patients compared to healthy indi-
viduals, regardless of treatment received (Table 1, “All 
patients” section). In order to thoroughly assess MDSC, we 
set up a flow cytometry panel covering markers for human 
myeloid cells (suppl. Fig. 1). By gating, we excluded line-
age positive (CD3+, CD19+ and CD56+) cells, doublet and 
dead cells. We observed significantly more HLA-DR− cells 
among monocytic CD14+ cells from melanoma patients 
compared to HD (Fig. 1a–c, *p < 0.05). As this mela-
noma patient cohort received different treatments, they are 
marked in the figure legend. The gate for HLA-DR− cells 
was set individually for each donor according to the refer-
ence gates drawn (suppl. Fig. 1).
Despite that we were able to recruit several elderly 
HD, it was not enough to reach a fully matched age dis-
tribution between HD and patients. However, there was no 
age-dependent alteration of monocytic MDSC frequency 
(suppl. Fig. 2). In an attempt to more precisely match both 
cohorts, we subtracted the HD and patients younger than 
32 from the analysis, resulting in a median age of 50 years 
for HD and 63 years for patients. Again, the frequencies 
of monocytic MDSC were significantly higher in patients 
compared to HD (suppl. Fig. 3).
The lin− CD14+ HLA-DR− cells were then tested with 
an antibody specific for IL-4R-alpha (CD124). In patients 
as well as HD, we observed CD124 expression (suppl. 
Fig. 4).
Chemotherapy or cytokine-based therapies might influ-
ence MDSC generation and recruitment or lead to further 
maturation of these cells in vivo [31, 39–42]. Therefore, we 
performed a subgroup analysis in patients that received no 
treatment except tumor surgery. We found a trend toward 
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the enrichment of lin− CD14+ HLA-DR− cells in patients 
prior to treatment when compared to HD (Fig. 2a), mainly 
due to smaller sample numbers available. Furthermore, we 
observed a trend for accumulation of lin− CD14+ HLA-
DR− cells in peripheral blood of tumor-bearing patients 
compared to patients after tumor resection (Fig. 2b), with-
out reaching statistical significance.
MDSC frequencies are not modified by ipilimumab 
treatment, do not depend on baseline LDH levels, but tend 
to differ between metastatic sub stages
We analyzed lin− CD14+ HLA-DR− monocytic MDSC at 
baseline and over several time points during and after ipili-
mumab treatment. We did not observe significant changes 
in frequencies of lin− CD14+ HLA-DR− cells (Fig. 3a, b). 
Suppl. Fig. 5 shows MDSC frequencies at baseline and 
during treatment for seven representative patients, i.e., the 
ones of whom baseline samples were available. Responders 
and NR are marked in the legend. Staining of monocytic 
cells with anti-CTLA-4 mAb was negative for HD and 
patients (suppl. Fig. 6), speaking against a direct effect of 
ipilimumab treatment on this cell population.
Since serum LDH correlates with tumor burden in 
advanced melanoma, we asked whether patients pre-
senting with an increased serum LDH level before treat-
ment accumulate higher numbers of MDSC. Our results 
showed no significant difference in overall frequency of 
lin− CD14+ HLA-DR− cells among patients with normal 
versus high serum LDH level at baseline (Fig. 3c). When 
comparing baseline frequencies of MDSC with the cor-
responding baseline LDH values, also no correlation was 
found (p = 0.21, data not shown). Finally, we addressed 
the question, whether the metastatic substage (stage IV 
M1a vs. M1b vs. M1c) had any impact on the accumu-
lation of MDSC. We observed a trend toward less lin− 
CD14+ HLA-DR− cells in patients having distant metas-
tasis in the skin or lymph nodes only (stage IV M1a) 
compared to patients having distant metastasis in other 
vital organs or increased LDH (stage IV M1c) (Fig. 3d 
p = 0.069). M1a stage patients showed lin− CD14+ HLA-
DR− cell frequencies comparable to HD. Of note, there 
was a subpopulation of patients with M1b and M1c stage 
disease who were mostly clinical NR with increased fre-
quencies of lin− CD14+ HLA-DR− MDSC. In the next 
step, we analyzed clinical responders and non-responders 
separately (***p < 0.001).
Low frequencies of MDSC are associated with clinical 
responses to ipilimumab treatment
About 11–13 % of patients treated with ipilimumab achieve 
objective tumor responses [8, 15]. CR, PR and stabilization 
of disease (SD) were reported [8]. Responding patients are 
shown to have a significantly augmented T cell frequency, 
activity and function [13, 22, 24, 43]. So far, several bio-
markers are published to correlate with clinical outcome 
after ipilimumab treatment [14, 18, 19, 21]. Most studies 
focused on T cell-mediated effects of ipilimumab. As T cell 
extrinsic pathways via CD80/CD86 may be also targeted by 
ipilimumab treatment, we focused on myeloid cell kinet-
ics during ipilimumab treatment. Interestingly, our data 
revealed significantly lower percentages of lin− CD14+ 
HLA-DR− MDSC in patients responding to ipilimumab 
treatment compared to NR (Fig. 4a, *p < 0.05). When com-
paring baseline values with average values during and after 
ipilimumab treatment, we found a trend of lower values in 
responders as compared to NR (Fig. 4b). However, patient 
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numbers were small, and the differences were not statisti-
cally significant, precluding conclusions.
Of note, we detected higher frequencies of lin− CD14+ 
HLA-DR− cells in patients with higher metastatic burden 
(Fig. 3d). This could be associated with bad clinical out-
come and thus introduce a bias in our data analysis. How-
ever, both the responder as well as the non-responder group 
contained stage M1a, M1b and M1c patients (Fig. 4a, b). 
When focusing exclusively on samples from patients with 
high metastatic load (stage IV M1c), we detected a trend 
toward lower frequencies of monocytic lin− CD14+ HLA-
DR− cells in ipilimumab responders as compared to NR 
(Fig. 4c, p = 0.062), however, without reaching statistical 
significance, likely due to small sample numbers.
Overall, our data show accumulation of monocytic 
MDSC in melanoma patients. Frequencies of monocytic 
MDSC tended to increase with metastatic spread. More 
importantly, frequencies of monocytic MDSC in mela-
noma patients correlated with their clinical response to 
ipilimumab treatment, which should be validated in follow-
ing studies including larger patient cohorts.
Discussion
In the present study, we set out to perform a detailed flow 
cytometry analysis of MDSC in patients with cutaneous 
melanoma, with a special focus on potential effects of anti-
CTLA-4 therapy consisting of 4 3-weekly cycles of ipili-
mumab (Yervoy®) at 3 mg/kg. In order to avoid in vitro 
artifacts due to freezing–thawing procedures and delayed 
blood processing, we analyzed fresh blood samples directly 
after withdrawal. We optimized the analysis for monocytic 
MDSC by using PBMC prepared with conventional den-
sity gradient centrifugation, as MDSC are purified together 
with mononuclear cells. This procedure is an alternative to 
whole blood stainings, where a higher background due to 
less pure cell fractions is a common obstacle.
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the treatment. Symbols in the figure correspond to either 1 blood sam-
ple per patient or the average frequency from several blood samples 
obtained per patient. *p < 0.05
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In concordance with the literature, we found that mono-
cytic lin− CD14+ HLA-DR− MDSC were significantly 
enriched in PBMC from melanoma patients compared to 
HD [30–32]. This difference occurred only as a trend when 
comparing HD and untreated patients, likely because fewer 
samples were available from untreated patients. As some of 
the vemurafenib-treated patients show higher frequencies 
of lin− CD14+ HLA-DR− cells, we cannot exclude a pos-
sible relationship between this treatment and high MDSC 
frequencies. We did not have enough patients and samples 
to follow this trend, but, most importantly, vemurafenib 
patients do not account for the significant difference in 
frequencies of lin− CD14+ HLA-DR− cells in melanoma 
patients and HD, as this difference remains significant 
when vemurafenib-treated patients were excluded from 
the analysis. Confirming our results, Mandruzzato et al. 
[44] identified IL-4R-alpha expression on monocytic cells 
enriched in cancer patients compared to healthy controls, 
but as opposed to our data no HLA-DR expression was 
assessed.
We observed a trend pointing toward enrichment of 
monocytic MDSC in patients with tumor burden, compared 
to tumor-free patients. In line with this, for patients with 
non-active disease, reduced frequencies of CD14+ HLA-
DR− MDSC have been described for melanoma patients 
and of CD14− CD33+ CD11b+ MDSC for patients with 
breast cancer [30, 45].
So far, very few is known about MDSC frequencies in 
melanoma patients treated with ipilimumab. It is important 
to study how MDSC behave in the context of an environ-
ment with increased T cell activity, in order to estimate 
drug-induced changes in the myeloid cell compartment 
of patients. For example, T cells from ipilimumab-treated 
patients secrete higher amounts of IFN-γ [23] which is 
known to recruit MDSC [37]. Therefore, one could expect 
that ipilimumab-treated patients accumulate higher MDSC 
frequencies. In contrast, our data show no significant dif-
ferences in MDSC frequencies over time in ipilimumab-
treated patients, indicating that these cells are tightly reg-
ulated. In contrast, the patient-to-patient variability was 
high, even among patients with the same tumor staging.
When testing the potential of ipilimumab as neoadju-
vant in stage III b-c patients, a drop of MDSC frequen-
cies 6 weeks after treatment induction was reported [46]. 
Furthermore, Tarhini et al. have analyzed several MDSC 
subsets in melanoma patients receiving the anti-CTLA-4 
antibody tremelimumab together with IFN-α. In contrast 
to our study, a decrease in frequency of monocytic MDSC 
was seen at days 29 and 85 [47] when cryopreserved sam-
ples were used. We analyzed fresh PBMC, immediately 
after blood withdrawal from patients and healthy con-
trols, because our results with cryopreserved cells were 
inconsistent (manuscript in preparation). Besides technical 
differences, there are further reasons why the studies are 
not directly comparable. For example, different ipili-
mumab dosing was used in the neoadjuvant study, and anti-
CTLA-4 therapy was conducted in combination with IFN-α 
in the tremelimumab study.
Most probably, T effector and T regulatory cells are 
the most direct targets of anti-CTLA-4 therapy. However, 
CTLA-4 expression has been observed in small quantities 
on the surface and more pronounced intracellular in mono-
cytes [48, 49], suggesting that ipilimumab could eventu-
ally act on monocytes or MDSC directly. Comin-Anduix 
et al. reported changes in the phosphorylation status of p38, 
ERK1/2, Stat-1, Stat-3 and Stat-5 in monocytes of patients 
treated with the anti-CTLA-4 antibody tremelimumab. 
Furthermore, monocytes of clinical responders and NR to 
tremelimumab differed in phosphorylation levels of Akt 
and Stat-6 [49]. In contrast to these observations, our study 
did not reveal CTLA-4 expression on monocytic cells and 
also no changes of MDSC frequencies were induced by 
ipilimumab treatment.
We did not find any correlation between serum LDH lev-
els at baseline and accumulation of MDSC in blood of mel-
anoma patients. If MDSC recruitment is altered in patients 
with higher serum LDH levels, reflecting strongly progres-
sive disease, this might take place only in the tumor micro-
environment, remaining undetectable in the blood.
Patients with bulky metastatic disease (M1c) showed a 
trend toward higher frequencies of monocytic MDSC than 
patients with metastases limited to skin and/or lymph nodes 
(M1a). For the more immature MDSC population of lin− 
CD33+ CD11b+ cells, this correlation has been described 
already in a patient cohort comprising of different malig-
nancies [50]. Interestingly, in our study, patients with stage 
IV M1a metastatic disease showed MDSC levels compara-
ble to HD, indicating that MDSC increased only later, i.e., 
with tumor spread to visceral sites, beyond skin and lymph 
nodes. This might involve tumor secreted VEGF, known 
to play a role in MDSC recruitment [51]. Possibly, higher 
amounts of MDSC might facilitate metastasis formation, 
e.g., by creating an immunosuppressive environment.
When distinguishing clinical responders and non-
responders within the different metastatic stages, we identi-
fied a subgroup of M1b and M1c patients. These patients 
had higher frequencies of monocytic MDSC and were 
mostly clinical non-responders. The subsequent analysis 
of clinical responders and non-responders addressed this 
effect.
Clinical benefit of ipilimumab treatment can take months 
to develop. Initially, tumor lesions might even increase in 
size due to local recruitment of immune cells and inflam-
mation [16]. Therefore, the tumor response evaluation by 
standard RECIST criteria at week 12 after treatment may 
not reflect actual anti-tumor activity. As recommended 
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recently, we applied the immune-modified RECIST cri-
teria [17] and evaluated the tumor response by CT scans 
performed at week 12, 16 and/or 24 after treatment. Our 
immune monitoring of patients treated with ipilimumab 
focused on identifying biomarkers associated with clinical 
response, with the aim of finding predictive markers. Our 
data show for the first time that MDSC frequency in PBMC 
of melanoma patients with ipilimumab treatment correlates 
significantly with the patient’s clinical response. This is 
also observed as a trend in patients with highly aggressive 
bulky metastatic disease (M1c), whose treatment options 
were very limited before the introduction of ipilimumab.
In contrast to our study, the frequency of the more 
immature lin− HLA-DR− CD33+ CD11b+ MDSC was 
reported to decrease stronger in patients responding to 
tremelimumab in combination with IFN-α [47]. For the 
reasons mentioned above (different patient treatments, dif-
ferent laboratory techniques), the results of the studies can-
not be compared directly.
It has been shown previously that patients with high 
baseline expression levels of immune-related genes and an 
immune-active tumor microenvironment in tumor tissue are 
more likely to respond favorably to ipilimumab [52]. Our 
data on peripheral blood are in line with this observation, 
as they show that patients with low frequencies of MDSC, 
implying less immune suppression and better reactivity, 
have improved clinical outcome.
Recently, a correlation between the frequency of CD14+ 
HLA-DR− cells and overall survival could be detected in 
renal cell carcinoma patients [53]. Furthermore, frequen-
cies of lin− HLA-DR− CD33+ CD11b+ MDSC correlated 
with overall survival in patients with pancreatic and esoph-
agogastric cancer [54]. In contrast, our data did not reveal 
significant correlations between MDSC frequencies and 
overall survival. To our knowledge, we provide the first 
evidence that MDSC frequencies in PBMC correlate with 
clinical response to treatment with ipilimumab. Although 
our study was retrospective and involving a relatively small 
number of patients, it suggests that MDSC frequencies cor-
relate with outcome of anti-CTLA-4 treatment. Prospective 
clinical trials assessing MDSC subpopulations and frequen-
cies as potential biomarkers of response to CTLA-4 block-
ade are therefore warranted to validate our observations.
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